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Difficult tumor inspires varied approaches

Creative strategies key in fight against
liver cancer
Liver cancer remains one of the most challeng- the tumor. However, only 20 to 30 percent of
ing tumors faced by the oncologist. Ninety-four liver tumors are completely resectable, said Mark
percent of people who are diagnosed with primary S. Roh, M.D., associate professor of surgery and
liver cancer die as a result of it. The majority of chief of Liver Tumor Surgery, also in the Departpatients with hepatocellular cancer, the most com- ment of Surgical Oncology. The tumors may be
mon type of liver tumor, do not live even a year too large to remove or in an awkward location,
after diagnosis. There are two problems behind perhaps surrounding an essential blood vessel.
these discouraging statistics: first, because the liver Cirrhosis, too, can make resection impossible.
is such a large organ, tumors can grow quite large Thus, in most cases, another treatment approach
before they start causing symptoms and are diag- is necessary.
nosed. By then, it is often too late for curative
Unfortunately, traditional nonsurgical therapy
treatment. Second, many traditional cancer treat- options, such as radiation therapy and chemoments are toxic to the normal liver tissue or to therapy, have had disappointing results in liver
Steven A. Curley is chief of
other tissues when they are given in doses suffi- tumors. Standard radiation treatments are toxic
Gastrointestinal Tumor
Surgery
cient to kill the tumor.
to the liver long before they have an effect on the
One physician who refuses to be daunted by · tumor; there is a high risk of liver failure. Simithese statistics is Steven A. Curley, M.D., associ- larly, systemic chemotherapy produces toxic ef- ·
ate professor of surgery and chief of Gastrointes- fects in other organs before it affects the tumor.
tinal Tumor Surgery in the Department of Surgical "No matter what kinds of drugs are used, the
Oncology at The University ofTexas M. D. Ander- results are pretty dismal," Curley said. "Usually
son Cancer Center. "I got interested in liver tu10 percent or less of the patients respond to
mors because they are such a major clinical systemic chemotherapy."
problem," Curley said. "There are no good treatments." His interest arose at the University of Regional chemotherapy minimizes side effects
New Mexico, where he did both his surgical trainFor treating liver metastases from stomach or
ing and laboratory research on the kinetics of pancreatic cancers, whole-body treatment is nectumor cell growth. In 1988, he came to M. D. essary because the cancers often will have metasMark S. Roh is chief of
Liver Tumor Surgery
Anderson Cancer Center to focus on liver tumor tasized elsewhere. For primary liver tumors,
treatments. Curley now divides his time between however, systemic toxicity has limited the tolertreating patients with hepatobiliary cancers or able dose of standard chemotherapy drugs H
t
_ _ _ _ _ __ _ __ ____.olorectal cance~ch commonly me
to the liver) and working in the laboratory to find tors are therefore trying to deliver high-dose chebetter therapies. He and his colleagues at M. D. motherapy directly to the liver. Yehuda Z. Patt,
Anderson have developed some alternative ap- M.D., associate professor of medicine and chief of
proaches to treating liver cancer that they hope the Regional Therapy Service in the Department
will prolong patient survival.
of Gastrointestinal Oncology and Digestive Diseases at M. D. Anderson, found that infusing
Surgery is f"rrst line of treatment
drugs directly into the liver through the hepatic
When a liver tumor is diagnosed, the first treat- artery would dramatically shrink tumors in a carement considered is complete surgical removal of fully selected subset of patients with advanced
Treatment Update

continued on page 2
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"Multidisciplinary strategies in liver
cancer are made possible by the team
efforts of 12 to 15 specialists."
the rest of the body does not. The infusion and
the filtering are done through catheters in the
neck and groin.
In trials, this system allowed delivery of doses
of doxorubicin of 120 mg/m2, twice what can
normally be tolerated by patients. Seven of ten
patients had a reduction in tumor volume of at
least 25 percent; in two patients, Curley was able
to resect a tumor that had previously been
unresectable . Now he is awaiting Food and Drug
Yehuda Z. Patt is chief of
Administration approval to add mitomycin C and
the Regional Therapy ,
cisplatin to the doxorubicin to try to increase the
Service
effectiveness of the treatment even more. Both
these agents have shown activity against hepatocellular cancers, and the three-drug combination
has shown promise in hepatic arterial infusion
studies.
Curley is also planning a clinical study of a
drug-delivery medium called matrix collagen gel.
This compound, when mixed with a chemotherapy
drug like cisplatin, encapsulates the drug; the
drug then does not disperse into other tissues
when it is injected into the tumor. "Again, we get
higher doses of the chemotherapy drug
in the tumor but reduce the dose of drug
that goes to the rest of the body," Curley
said. Tumor kill is enhanced, while side
-POST-FILTER
effects are minimized. Pilot studies of
SAMPLES
this technique were done at M. D . Anderson; although measuring patient response
was not a primary focus of these studies,
CARBON FILTEAS
Curley noted that in all 20 patients the
size of tumor was reduced at least 50
CATHET
percent, and in nine the reduction was at
TIP INTHE
PROPER
HEPATIC
least 90 percent.
ARTERY
ORTA
Researchers are also trying other drugs
INFERIO
that attack the tumors in different ways.
VEN
CAV
Curley has begun studying some experi(!~~ CAPACITANCE
mental compounds that, rather than being
PUMP
directly toxic to the hepatocellular canCHEMOTHERAPYDRUG
cer cells themselves, m ay cause the nort
mal liver cells (hepatocytes) to excrete
substances that slow or retard the growth
of the cancer cells. These compounds
have had promising results in clinical trials in Europe, producing anticancer
Delivery system used for hepatic arterial infusion of chemotherapy with complete hepatic venous
responses.
Curley will study the interisolation and extracorporeal chemofiltration . (Reprinted with permission from The Cancer Bulletin.
Copyright 1994, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.)
action of the compounds with normal
hepatocellular cancer. In 12 of 31 patients, hepatic arterial infusion of FLAP-a combination of
floxuridine (FUDR), leucovorin, doxorubicin
(Adriamycin), and cisplatin (Platinol )-decreased
tumor size by more than 50%. In several patients,
tumors that were originally unresectable became
resectable after treatment with FLAP. Patients
who did not have hepatitis B or C infection survived an average of more than three years after
this treatment, while patients who were positive
for hepatitis B or C experienced complications
during treatment. In modified doses, however,
this regimen may prolong life for hepatitis patients who had an adequate amount of healthy
liver before treatment.
Curley has been studying a system that combines this hepatic arterial infusion technique with
hepatic venous isolation and extracorporeal
chemofiltration. A chemotherapy drug is infused
into the liver through the hepatic artery; the blood
coming out of the liver is then captured and
filtered to remove the drug (see figure). Thus the
liver and tumor get a high dose of the drug, but

...-.c--=----=.-=--->.~

page 2

April-June 1995

Current Liver Cancer Protocols
CPP / GS 94-001 ....... Current practice of cryosurge ry for unresectable hepatic metastases (Study chairman : Dr. Roh)
OM 89-064 .......... .. .. A Phase II trial of intravenous 5-fluorouracil and subcutaneous recombinant interferon -u for treatment of fibrolamellar hepatoma and cancer of the biliary tree
(cholangiocarcinoma and gall bladder carcinoma) (Study chairman : Dr. Patt)
ID 92-024 .. ... .... .. .... . A Phase II trial of hepatic arterial infusion of floxuridine (FUDR), leucovorin,
doxorubicin (Adriamycin), and cisplatin (Platinol) for the treatment of hepatocellu lar cancer confined to the liver (Study chairman : Dr. Patt)
OM 93 -137 ........ .. ... . A case -control study of hepatitis C virus and its interaction with hepatitis B virus in
the development of hepatocellular cancer in H arris County, Texas (Study chairman :
Dr. Patt)
ID 93 -024 .... ....... .. ... A two-arm Phase II trial of cisplatin (Platinol) , recombinant interferon -u, doxorubi cin (Adriamycin), and 5-fluorouracil for the treatment of hepatocellular cancer : arm
A by hepatic arterial infusion, arm B by systemic administration confined to the liver
(Study chairman: Dr. Patt)

hepatocytes and with hepatocellular cancer cells
in the laboratory to determine whether they indeed produce an effect and, if so, how they can be
used to treat cancer patients. ·
Cryotherapy takes up where surgery leaves off
Roh, with Bruno D. Fornage, M.D., of the
Department of Diagnostic Radiology, has helped
a number of patients with liver tumors-including metastases from colorectal cancers, hepatomas,
and sarcomas-by using cryosurgery. "I cut out
what I can and freeze the remainder of the tu mor," he said. This technique, which was developed in Boston and Pittsburgh in the late 1980s,
involves inserting into the tumor a thin probe that
fills with liquid nitrogen, freezing the surrounding tissue. The freezing (at least 10 minutes at 30°C) destroys the tumor tissue, which is then
slowly absorbed by the body over time. The probe
insertion and freezing process are monitored precisely by ultrasound.
"It's quite well tolerated," Roh said. Since
September 1993, he has performed cryosurgery
on about 35 patients. "This treatment is exciting
because it increases the number of patients who
can be treated with potentially curative therapy,"
Roh said. Initial data suggest survival rates as
good as those for patients who undergo surgical
resection.
Radio-frequency current destroys tumors
In the laboratory, Curley is studying another
technique called bipolar radio frequency ablation
(BRFA). "It's the opposite of cryosurgery," he

explained. "Instead of freezing the tumor, we're
heating it." Two needles are placed in the liver,
one on each side of the tumor, and a radio frequency current is run through the tumor, coagulating it. As for cryosurgery, the dead tumor tissue
is slowly absorbed by the body over time. The
potential advantage over cryosurgery is that the
needles used are much smaller than cryosurgery
probes and therefore less traumatic to the liver.
In the United States this research is still in the
preclinical stage; Curley is studying BRFA in pigs.
"When it comes to the anatomy of the liver and
blood vessels, pigs are strikingly similar to humans," he said. The technique has been used in
patients in Asia and Europe. "It looks promising," Curley said, "but these are early studies."
Early detection and new research are increasing options
"Promising" means a lot when there are so few
good treatment options for patients with liver
cancer. The chances for the patient would be
better if the tumors were detected earlier, when
there are more options for therapy. "We're doing
better at early detection by screening patients at
higher risk with blood tests and ultrasound,"
Curley said. People appropriate for such screening include those with cirrhosis or chronic hepatitis B or C infection.
Because the cancer is usually advanced by the
time it is diagnosed, any treatments that even
prolong survival could benefit the patient, Curley
said. He feels that multimodality treatments will
be the key to success. A significant number of
continued on page 7
page 3
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Primary care physicians play an important role in prevention

Teaching physicians how to prevent
cancer
Prevention

Robert M. Chamberlain is
director of the Cancer
Prevention Education and
Teaching Program

Ten years ago, a physician might have seen a
tanned teenager with a broken arm and just treated
the arm. "These days it would not be unusual for
the physician to also counsel the patient about the
possible harmful effects of tanning," said Robert
M. Chamberlain, Ph.D ., associate professor of
cancer prevention and Director of the Cancer
Prevention Education and Teaching Program at
The University of Texas M . D . Anderson Cancer
Center. Our increasing knowledge of how cancer
arises has enabled us to devise effective ways to
prevent it. However, physicians themselves must
be taught how to prevent cancer before they can
advise their patients about it; through research
and training, this is the mission of the Cancer
Prevention Education and Teaching Program.
Until recently cancer prevention was not part
of medical school curricula. When Chamberlain
began his work in cancer education ten years ago
at Baylor College of Medicine, most medical students never even saw untreated cancer patients.
Even today, most medical students learn about
cancer only in basic science courses such as Cell
Biology and Introduction to Medicine. They seldom receive formal training in how to diagnose or
prevent cancer unless they intend to become
oncologists. Chamberlain pointed out, "Many
physicians graduated from medical school never
having palpated a breast lump. Most medical students saw breast cancer patients only after surgery. If you weren't on duty before the patient
had surgery, you missed it."
Texas a leader in cancer prevention education
If you were a medical student or have practiced
medicine in Texas, you (and your patients) may
have been luckier than most. "Nationally, Texas
has been a leader in cancer prevention education.
In fact, we had the national meeting for the
American Association for Cancer Education in
Houston in 1993," said Chamberlain, who is
secretary of the association. "People were amazed
at how much is going on in Texas, much of it
thanks to the Texas Cancer Council." In 19 8 7,
Joseph T. Painter, M.D., then Vice President for
Health Policy at M . D. Anderson Cancer Center,
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ensured that funding for cancer research and education became a line item in the Texas state budget by forming the Council, which funds cancer
education. As a result, Texas educators have addressed the gaps in physicians' knowledge about
cancer prevention in several ways.
At Baylor, Ghamberlain helped organize an
elective class devoted to cancer for the medical
school curriculum. The medical students themselves may have recognized the need for the class:
it rapidly became the most popular elective. Over
half of the students took it, and more would have
if the classroom had been larger. The class has
become a model for other medical school classes
throughout the nation.
First step: physician education
In 1988 Chamberlain moved to the Division
of Cancer Prevention at M. D. Anderson, which
had already begun to educate primary care physicians in cancer prevention. He later became part
of the newly formed Department of Epidemiology within that division. Margaret R. Spitz, M.D.,
M.P.H., professor of cancer prevention and acting chairman of the Department of Epidemiology, and the late Guy R. Newell, M .D., M.S.Hyg.,
then chairman of the Division of Cancer Preven tion, had written a loose-leaf guidebook for physicians called ReCaP: Recommendationsfor Cancer
Prevention. ReCaP begins with an overview of
cancer trends in the United States and a brief
introduction to cancer screening. Separate chapters are devoted to the most important cancer
sites: breast, cervix, endometrium, colorectal system, head and neck, lung, skin, and prostate.
Each chapter begins with graphs showing the
incidence and survival rates for that cancer. Then,
the risk factors for that cancer are discussed and
prevention strategies are outlined.
The Texas Cancer Council distributed copies
of ReCaP to 10,000 primary care physicians in
Texas. A mail-back card in the book solicited
feedback on its usefulness. ReCaPproved to be so
helpful to these physicians that eventually it was
published for nationwide distribution by MosbyYear Book. "It is now the family physician's desk
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"While many are aware of the need to educate
their patients about how to reduce their risk of
developing cancer, it is not always clear to busy
physicians what they should do."
reference book for cancer," said Chamberlain.
(Instructions for obtaining the book are provided
at the end of this story.)
Chamberlain used the successful ReCaP formula to address the remaining weak link in cancer
education for physicians-resident training. He
helped develop and test ReCaP for Residents, a
complete cancer course consisting of an instructor's
manual with slides and outlines of lectures. With
the detailed information in ReCaP for Residents,
an instructor can prepare a one-hour lecture in
only about one hour's time. ReCaP for Residents
is currently used in about 100 primary care residency programs in this country.

Training opportunities for physicians in
practice
But what about the physicians already in practice who missed tl1ese educational opportunities?
While many are aware of the need to educate their
patients about how to reduce their risk of developing cancer, it is not always clear to busy physicians what they should do. For instance, it may
seem obvious that a physician in Miami should
spend more time educating patients on the dan gers of tanning and skin cancer than a doctor in
Minneapolis. However, other risk factors and practices may not be so obvious. For example, few
physicians can say what percentage of their women
patients are complying with the National Cancer
Institute guidelines for mammography screening.
"Primary care physicians see patients one at a time
and only rarely collect statistics on compliance,"
said Chamberlain.
-----S-u-tlra-r-physi-cians-donor-have-ro--read-af-l-t.heirpatient records to collect this information, Cham berlain created Profile, a computerized system
that ascertains the cancer risk profile of all adult
·
·
di al
• T
outpatients, as a gr~~p, ma me c practice. 0
use Profile, a phys1c1an or
, office staff member
~andomly selects 200 patie~t charts an~ e_nters
mto the computer such patient characteristics as
sex, age, history of smoking-, family history of
cancer, dates of last mammogram and Pap smear,
and date oflast prostate examination. Profile then
compares this information to the National Cancer

Institute guidelines and tells the physician which
screening tests or other prevention strategies
should be emphasized in that practice. Chamberlain estimates that the risk profile of a practice is
accurate for about two years or until the composition of patients in a practice changes significantly.
In some cases, a physician's solution to better
cancer prevention may be as simple as placing in
the waiting room pamphlets from the American
Cancer Society or the National Cancer Institute.
For physicians who want to improve their own
understanding of cancer prevention, Chamberlain recommends consulting ReCaP and taking
Continuing Medical Education classes. "Physicians, researchers, and other professionals in the
Houston area are also welcome to attend our
Friday morning cancer preve_ntion seminars," invited Chamberlain.
Two of the offerings of the Cancer Prevention
Education and Teaching Program are a multiyear
predoctoral and postdoctoral fellowship and a
three-month fellowship for graduate students in
any field related to cancer prevention. Both fellowships are funded by the National Cancer Institute. Each fellow chooses a mentor from the
M. D. Anderson faculty, works in the mentor's
lab or on his or her project, and participates in
seminars and courses on cancer prevention research. In this way, M. D. Anderson faculty prepare for the next generation of cancer prevention
strategies.
-MAUREEN

E.

GOODE

- Physi-cians-who---des-i-re-me>re-inf-e>r-mation- on- eanee
prevention training fellowships or attending the cancer
prevention seminars ma! wri!e Dr. Chambe:lain~ Box
189, Department of Ep1dem10logy, The Uruvers1ty of
TexasM. D. Anderson Cancer Center, 1515 Holcombe
Blvd., Houston, TX 77030, or call (713) 792-3020.
The book R e a p : R ecommenda t·ions fior ancer p revention, by Margaret R. Spitz, M.D., and Guy R.
Newell, M.D., can be obtained from the publisher,
Mosby-Year Book, Inc., 11830 Industrial Drive, St.
Louis, MO 63146, or from medical bookstores. Specify
ISBN 0-8016-6704-6. ■
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Ambulatory Surgery
continued from page 8

Range of surgical procedures available
M. D. Anderson surgeons are electing to perform a variety of operations on an outpatient
basis. Most breast cancer surgeries can now be
performed through the Center, including
lumpectomies, simple mastectomies, and modified radical mastectomies. Other outpatient procedures include biopsies, dental surgeries, bone
marrow aspiration procedures, revisions to facial
and breast reconstruction, bronchoscopies, excisions of head and neck lesions, and many others.
In a recent survey, 50 M. D. Anderson surgeons
indicated that the Center could have provided a
treatment option for about one third of the 8,470
surgeries performed here in 199 3.
Kim Vidor, M.S., R.N., C.N.O.R., administrative coordinator of the Ambulatory Surgery Center, recounted that 15 years ago, when she first
came to M. D. Anderson, breast cancer patients
were hospitalized for up to 12 days after surgery.
In recent years, patients have been required to
stay only 3 to 4 days. But with the range of
support services M. D. Anderson provides, such
as preoperative training for patients and family
members, and the advanced anesthesia and surgi-

A procedure in progress in the Ambulatory Surgery Center while Dr. Moss
(in background, facing camera) looks on.
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cal capabilities provided through the Center, some
patients are able to go home in an even shorter
period of time.
Moss explained that every patient in the Center's
recovery room is continuously monitored, which
offers a safety net not found in all institutions.
Patients must meet certain criteria before they can
be discharged. The exact duration of the patient's
hospital stay depends on the type of surgery performed and how well and how soon the patient
responds. Some patients are discharged directly
from the postanesthesia unit, while others are
transferred to another recovery area for overnight
observation. The service is still considered outpatient if the patient is discharged within 23 hours
of arrival at the hospital. If complications do arise,
the patient can be admitted as an inpatient for
further treatment.
Located in Station 44 on the fourth floor of
M. D. Anderson's Clark Clinic, the Center has
already assumed a large percentage of the hospital's
surgical volume. "On a monthly basis, we perform 25% to 33% of the total bookings for the
hospital's operating rooms, and we work out of
only three of the 19 rooms designated for surgery," Moss reported.
Robert Jones, M.D., chairman of the Department of Anesthesiology and Critical Care and
medical director of the Ambulatory Surgery Center, estimated that "3,000 surgeries had been performed in the Center by the end of 1994. Once
construction is complete on new surgical suites
that are part of an M. D. Anderson expansion
project, additional space will be available to the
Center, and this volume will probably increase.
State-of-the-art anesthesia and pathology
services offered
The success of the Center is a testament to
M. D. Anderson's goal of constantly improving
the quality of patient care. Three factors that have
been particularly beneficial to Center patients are
M.D nnP~~n'
•
thology, and pharmacology services.
"We use the most up-to-date anesthesia management techniques available and appropriate in
the cancer setting," said Moss. "Likewise, M. D.
Anderson's pathologists can rapidly identify tumor types and analyze tissues because of their
experience with these specialized samples. The
level of expertise in these particular areas has been
essential to our implementation of a successful
outpatient surgery program. Also, improved anesthesia medications means patients are alert and
functional sooner. Patient recovery is further ac-
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"It is important that patients know
exactly what to expect before, during,
and after their procedure."
celerated by the use of more effective pain and
anti-emetic medications."

Training sessions for patients, friends,
and families
Although pleased with the implications of sameday discharge after surgery, patients naturally have
some concerns. Through specialized training sessions, the patient and a designated friend or fam ily member receive information about the surgical
procedure they are to undergo and instructions
regarding postoperative care. This service is essential because it gives all parties an opportunity to
clarify their roles in the caregiving scheme and to
become comfortable with outpatient surgery as a
treatment alternative. During the sessions, a hospital representative answers questions ranging from
"What type of anesthesia will I be given?" to
"How long will I be convalescent?"
Preoperative training is coordinated by Tomee
Keto, R.N., nurse clinician in the surgery scheduling clinic, who says it is important that patients
know "exactly what to expect before, during, and
after their procedure." Keto serves as a liaison
between the patient, the surgeon, and the anes-

thesiologist. She checks the patients' paperwork
to make sure it is complete, makes sure they know
when to arrive at the hospital and where to check
in, and describes what they will experience during
surgery, recovery, and observation. Her role, she
says, is "to make the patient feel as comfortable as
possible."
"Patient feedback has been very positive," said
Moss, "but then, patients don't typically have a
problem with a shorter hospital stay. As an institution constantly striving to improve on patient
care, we understand that cancer can have an enormous effect on a patient's life. With this service,
we hope to minimize that effect by shortening the
hospital stay and thereby minimizing the interruption of the patient's regular schedule."
-VICKIE

J. WILLIAMS

REFERRALS. Physicians who have questions or would
like to refer patients to the Ambulatory Surgery Center
may write Dr. Moss, Department of Anesthesiology
and Critical Care, Box 42, The University of Texas
M. D. Anderson Cancer Center, 1515 Holcombe Blvd.,
Houston, TX 77030, or call (713)792-6907. ■
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Liver Cancer
continued from page 3
patients develop recurrences in the liver or other
organs after surgery alone. "We need to combine
surgery with other treatments," he said. "For
example, if the tumor is small, we can do surgery
first and follow with chemotherapy. Or, if it is
large, we can use chemotherapy to reduce the size
of the tumor and then use surgery or radiation."
Such multidisciplinary strategies are made possible at M. D. Anderson by the team efforts of
12 to 15 specialists, including Curley, Roh, and
radiologist C. Humberto Carrasco, M.D., who
participate in a liver tumor study group chaired
by Patt. The group meets each week to discuss
their patients' treatments and future treatment
protocols.

The various lines of attack described here all
attempt to remove or dissolve the tumor. Novel
therapies down the road may be able to change
the behavior of the tumor so that it will regress on
its own or become more benign. "That's science
fiction now," said Curley, "but as we understand
the liver better, we'll be able to develop other
options."
-SUNITA PATTERSON

REFERRALS. Physicians who have questions or would
like to refer a patient may write Drs. Curley, Roh, or
Patt at the Departments of Surgical Oncology (Curley,
Roh) or Gastrointestinal Oncology and Digestive Diseases (Patt), The University of Texas M. D. Anderson
Cancer Center, 1515 Holcombe Blvd., Houston, TX
77030, or call (713) 794-4957 (Curley), 792-7961
(Roh), or 792-2828 (Patt). ■
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Ambulatory Surgery Center offers a wide range of procedures

Getting patients home and back to
their routines more quickly
Patient Care

Edward Moss is clinical
coordinator of the
Ambulatory Surgery
Center

Adjusting to a diagnosis of cancer often means
adjusting to a host of lifestyle changes. There are
new emotional, financial, and schedule considerations for the patient and the entire family. The
possibility of surgery can be particularly burdensome. To ease some ofthis burden, The Uni ersity of Texas M. D. Anderson Cancer Center has
established an outpatient surgical unit where a
range of procedures are performed and patients
are typically released the same day.
Disruption minimized by quick turnaround
Being sick can create all types of anxieties for a
patient, explained Edward Moss, M.D., associate
professor of anesthesiology and clinical coordina tor of M. D. Anderson's Ambulatory Surgery
Center, especially when the cause of the illness is
a major disease such as cancer and surgery is
prescribed. Parents of young children must arrange for their care. Patients who do not live in
the immediate treatment area must consider temporary accommodations for themselves and those
who will travel with them. Patients who work

must arrange for time off from th ir j b . Wh n
the duration of th hospital
·
·n th
patients' concerns about tim
a c 1erate.
The on - ar-old
nt r wa d ign d t ddress certain asp ct of urg ry that an tri
r
such anxieties. ' In g n ral p pl d n t lik
being in the hospital," aid M . Th h
deal with a separation from th ir famili
adapting to a ne ituation at a diffi ult p ri d.
· rvice i o g pa · n
home sooner. We ha e found that pati nts progre
quickly in their own homes and hen cared for b
loved ones."
Moss said that another goal in establishing the
Center was to respond to the managed care industry. "M. D. Anderson is looking for a s to
address managed care issues, one of which is cost.
By reducing the amount of time a patient has to
stay in the hospital, without sacrificing the quality
of patient care we can cut costs considerabl
which translates into benefits for both the insurance provider and the patient.
continued on page 6

